Inhibrx FCF yield
¿Qué es el FCF yield de Inhibrx?
El FCF yield de Inhibrx, Inc. es -18.58%
¿Cuál es la definición de FCF yield?
Free cash flow yield (FCF yield) is a financial ratio that compares the free cash flow per share to the market value per share. The ratio is calculated by dividing free cash flow per share by the current share price.
ttm (trailing twelve months)
Free cash flow yield is a good measure of the company’s cash flow in respect to the company’s size. Larger companies tend to have a higher cash flow yield, but it’s not always the case. The higher the free cash flow yield, the more cash the company is generating that can be quickly accessed to satisfy its obligations. The lower the free cash flow yield, the more money investors are putting into the company with little result. The higher the ratio, the more attractive the investment is as it suggests that investors are paying less for each unit of free cash flow.
Free cash flow acts as an indicator of how capable a company is of repaying all of its obligations. It is a solid indicator of how financially stable a company is. It is calculated as:
Free cash flow yield = Free cash flow per share / market price per share
FCF yield de compañías en Sector Health Care en NASDAQ en comparadas con Inhibrx
¿Qué hace Inhibrx?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Empresas con fcf yield similar a Inhibrx
- Defiance Silver tiene FCF yield de -18.63%
- Ivanhoe Electric Inc tiene FCF yield de -18.61%
- Thunderstruck Resources tiene FCF yield de -18.61%
- Western Forest Products tiene FCF yield de -18.60%
- PainChek tiene FCF yield de -18.60%
- Holders Technology plc tiene FCF yield de -18.58%
- Inhibrx tiene FCF yield de -18.58%
- Sparq Corp tiene FCF yield de -18.57%
- Maanshan Iron & Steel tiene FCF yield de -18.56%
- genedrive plc tiene FCF yield de -18.56%
- Kolibri Global Inc tiene FCF yield de -18.55%
- American Well Corp tiene FCF yield de -18.54%
- Enochian Biosciences Inc tiene FCF yield de -18.54%